Official Title
Effect of Vitamin D3 and Omega-3FA on Estradiol
Phase
N/ALead Sponsor
Applied Science Private University, Amman -JordanStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Vitamin D DeficiencyIntervention/Treatment
VD3 Omega3-FA VD3 and Omega-3FA [vitamin d3 (2809), omega-3 fatty acids (112407)] ...Study Participants
116The effect of vitamin D3 and omega-3 Fatty acids on estradiol levels.
The data about effect of vitamin D3 (VD3) and omega-3 fatty acids (omega-3FA) on serum levels of estradiol (E2) are scarce and conflicting and nothing is published in the literature about the effect of the combination of VD3 and omega-3FA on the E2 levels.
This study was conducted to investigate effect of VD3 and omega-3FA alone and with each other on serum E2 levels in premenopausal females with vitamin D deficiency (VDD).
This randomized, placebo-controlled clinical trial was designed to test effects of 50,000 IU VD3 weekly and 300 mg omega-3FA daily for eight weeks, separately and with each other, on the mid-follicular serum levels of E2 and 25-hydroxy vitamin D (25OHD). This study was conducted during winter in 86 healthy premenopausal Jordanian females with VDD with a mean age of (32.8 ± 8.9) years. Fasting serum levels for 25OHD, E2, PTH (parathyroid hormon), calcium, phosphate, ALT (alanine aminotransferase), and urea were assessed at baseline and the end of the trial.
50,000 IU VD3 / week for 8 weeks
300 mg of omega3-FA once daily for 8 weeks
50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
No intervention was given
1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
Inclusion Criteria: Premenopausal females Medical diagnosis of vitamin D deficiency (VD < 30 ng / ml) Exclusion Criteria: Women previously diagnosed with any chronic disease such as kidney diseases were excluded from the study due to the effect of prolonged administration of VD3 on kidney stones formation. Women who are pregnant, breastfeeding or using hormonal contraceptives were also excluded.